Assembly Biosciences Inc  

(Public, NASDAQ:ASMB)   Watch this stock  
Find more results for NASDAQ:VTUS
+0.17 (2.87%)
Jul 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.76 - 6.14
52 week 4.33 - 17.26
Open 6.00
Vol / Avg. 30,549.00/125,590.00
Mkt cap 102.99M
P/E     -
Div/yield     -
EPS -1.88
Shares 17.23M
Beta 0.85
Inst. own 77%
Jun 7, 2016
Assembly Biosciences Inc at Jefferies Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -34.14% -27.76%
Return on average equity -38.66% -32.09%
Employees 51 -
CDP Score - -


99 Hudson St Fl 5
NEW YORK, NY 10013-2993
United States - Map
+1-212-5544388 (Phone)
+1-646-7065101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing approximately two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate a number of Hemoglobin C functions. The Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice (cGMP) conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile-infections.

Officers and directors

Derek A. Small President, Chief Executive Officer, Director
Age: 39
Bio & Compensation  - Reuters
David J. Barrett CPA, Chief Financial Officer, Chief Operating Officer
Age: 39
Bio & Compensation  - Reuters
Lee D. Arnold Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
Uri Lopatin M.D. Vice President - Research & Development, Chief Medical Officer
Age: 43
Bio & Compensation  - Reuters
William R. Ringo Independent Non-Executive Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Alan J. Lewis Ph.D. Director
Age: 70
Bio & Compensation  - Reuters
Anthony E. Altig Independent Director
Age: 59
Bio & Compensation  - Reuters
Mark Auerbach CPA, Independent Director
Age: 76
Bio & Compensation  - Reuters
Richard DiMarchi Independent Director
Age: 62
Bio & Compensation  - Reuters